Forskellen i kroppens overfladeareal (1, 53 – 2, 32 m2) og samtidig behandling med CHOP kemoterapi, bidrog til den relativt ringe variation i V1 (27, 1% og 19, 0%).
This variability in V1 (27.1% and 19.0%) contributed by the range in BSA (1.53 to 2.32 m2) and concurrent CHOP therapy, respectively, were relatively small.